The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-6511
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats ; volume:21 ; number:1 ; day:16 ; month:11 ; year:2020 ; pages:1-15 ; date:12.2020
BMC pharmacology & toxicology ; 21, Heft 1 (16.11.2020), 1-15, 12.2020
- Urheber
-
Darweesh, Ruba S.
El-Elimat, Tamam
Zayed, Aref
Khamis, Tareq N.
Babaresh, Wahby M.
Arafat, Tawfiq
Sharie, Ahmed H. Al
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-020-00456-9
- URN
-
urn:nbn:de:101:1-2020122719234054207146
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Darweesh, Ruba S.
- El-Elimat, Tamam
- Zayed, Aref
- Khamis, Tareq N.
- Babaresh, Wahby M.
- Arafat, Tawfiq
- Sharie, Ahmed H. Al
- SpringerLink (Online service)
Ähnliche Objekte (12)
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib